Feed/Investors/Sanderling Ventures

Sanderling Ventures

The rounds this investor is named on, who it invests beside, and where it shows up.

Named on one round in the feed.

Dedicated to biomedical financing and active management

Venture capitalsanderling.comSince 2025-04-16

ROUNDS

joined, none as lead

ROUNDS JOINED · USD

$115M

across 1 round

LATEST ROUND

Series C · $115M · 2025-04-16

CO-INVESTORS

named beside it

Rounds

The rounds this investor is named on, who it invests beside, and where it shows up.

Glycomine develops replacement therapies for rare genetic diseases, particularly focusing on PMM2-CDG treatments.

Series C$115M2025-04-162 [ HISTORY ]

Company	Round	Amount	Announced	Role
Glycomine Glycomine develops replacement therapies for rare genetic diseases, particularly focusing on PMM2-CDG treatments.	Series C Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$115M	2025-04-16	[ PART ]